Intel Capital led a $14.1m round for the cancer diagnostics system provider, its parent company having already supplied it with artificial intelligence technology.
China-based pathology technology developer Konfoong Biotech International has closed a series B round led by semiconductor and data technology provider Intel sized at up to RMB100m ($14.1m), DealStreetAsia reported yesterday.
The corporate led the round through its Intel Capital subsidiary, participating alongside Zhejiang Xinganxian Media Investment, a vehicle for media group Zhejiang Daily Press, in addition to venture capital firm Yingxinggu Capital, according to a company statement.
Also known as KFBIO, Konfoong Biotech provides medical devices that scan and process…
